A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (ANTI-PD-L1 ANTIBODY)compared with Docetaxel in patients with non-small cell lung cancer after platinum failure
|Effective start/end date||11/20/13 → 12/31/20|
- Genentech Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.